Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Regulation of Hematopoietic Stem Cells01:01

Regulation of Hematopoietic Stem Cells

3.1K
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
3.1K
Abnormal Proliferation02:23

Abnormal Proliferation

4.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
Overview of Hematopoiesis01:20

Overview of Hematopoiesis

3.8K
Hematopoiesis, or blood cell production, is a vital biological process that begins early in embryonic development and continues throughout life. This process generates the various types of cells found in blood, including red blood cells, white blood cells, and platelets from hematopoietic stem cells (HSCs).
Developmental Phases of Hematopoiesis
Initially, HSCs are formed in the embryonic yolk sac, a critical site for early blood cell production. These stem cells subsequently migrate to other...
3.8K
Hematopoiesis01:21

Hematopoiesis

5.1K
The process of blood cell formation is called hematopoiesis. Hematopoiesis starts early during development, on the seventh day of embryogenesis. This phase of hematopoiesis is called the primitive wave, wherein the extraembryonic yolk sac allows the production of erythroid cells and endothelial cells from a common precursor called hemangioblast. The erythroid cells provide oxygen to support the growth of the rapidly dividing embryo. Hemangioblasts later develop into hematopoietic stem cells or...
5.1K
Role of Hematopoietic Growth Factors01:28

Role of Hematopoietic Growth Factors

1.3K
Hematopoietic growth factors are molecules that regulate the differentiation rate of hematopoietic stem cells (HSCs). Erythropoietin (EPO), primarily produced by the kidneys, plays a crucial role in erythrocyte production. When oxygen levels in the blood are low, EPO is released into the bloodstream, reaching the bone marrow, where it stimulates HSCs to differentiate and mature into erythrocytes, which are vital for oxygen transport.
Thrombopoietin (TPO), mainly released by the liver,...
1.3K
Alternative RNA Splicing02:18

Alternative RNA Splicing

21.0K
Alternative RNA splicing is the regulated splicing of exons and introns to produce different mature mRNAs from a single pre-mRNA. Unlike in constitutive splicing where a single gene produces a single type of mRNA, alternative splicing allows an organism to produce multiple proteins from a single gene and plays an important role in protein diversity.
There are five types of alternative RNA splicing that vary in the ways the pre-mRNA segments are removed or retained in the mature mRNA. The first...
21.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Circ0515 reprogramming mitochondrial succinate metabolism and promotes lung adenocarcinoma progression through regulating SDHB.

Cell death & disease·2025
Same author

Lactylation: From Homeostasis to Pathological Implications and Therapeutic Strategies.

MedComm·2025
Same author

m6A RNA methylation: a pivotal regulator of tumor immunity and a promising target for cancer immunotherapy.

Journal of translational medicine·2025
Same author

RNA N4-acetylcytidine modification and its role in health and diseases.

MedComm·2025
Same author

Prolonged 3D culture unlocks black box of primate embryogenesis.

Cell stem cell·2023
Same author

RETN gene polymorphisms interact with alcohol dependence in association with depression.

Journal of clinical laboratory analysis·2023

Related Experiment Video

Updated: Jun 9, 2025

Identifying DNA Mutations in Purified Hematopoietic Stem/Progenitor Cells
11:06

Identifying DNA Mutations in Purified Hematopoietic Stem/Progenitor Cells

Published on: February 24, 2014

13.0K

RNA modification in normal hematopoiesis and hematologic malignancies.

Xi Chen1,2, Yixiao Yuan3,4, Fan Zhou1,2

  • 1Department of Neurosurgery The Second Affiliated Hospital of Kunming Medical University Kunming China.

Medcomm
|October 24, 2024
PubMed
Summary

N6-methyladenosine (m6A) RNA modification is crucial in normal and malignant hematopoiesis. Targeting m6A regulators offers potential for precise and effective leukemia treatments.

Keywords:
RNA modificationhematopoietic stem cellsleukemia stem cellspotential targetssignaling pathway

More Related Videos

Engineering Oncogenic Heterozygous Gain-of-Function Mutations in Human Hematopoietic Stem and Progenitor Cells
12:04

Engineering Oncogenic Heterozygous Gain-of-Function Mutations in Human Hematopoietic Stem and Progenitor Cells

Published on: March 10, 2023

3.5K
Bone Marrow Transplantation Procedures in Mice to Study Clonal Hematopoiesis
08:00

Bone Marrow Transplantation Procedures in Mice to Study Clonal Hematopoiesis

Published on: May 26, 2021

12.3K

Related Experiment Videos

Last Updated: Jun 9, 2025

Identifying DNA Mutations in Purified Hematopoietic Stem/Progenitor Cells
11:06

Identifying DNA Mutations in Purified Hematopoietic Stem/Progenitor Cells

Published on: February 24, 2014

13.0K
Engineering Oncogenic Heterozygous Gain-of-Function Mutations in Human Hematopoietic Stem and Progenitor Cells
12:04

Engineering Oncogenic Heterozygous Gain-of-Function Mutations in Human Hematopoietic Stem and Progenitor Cells

Published on: March 10, 2023

3.5K
Bone Marrow Transplantation Procedures in Mice to Study Clonal Hematopoiesis
08:00

Bone Marrow Transplantation Procedures in Mice to Study Clonal Hematopoiesis

Published on: May 26, 2021

12.3K

Area of Science:

  • Molecular Biology
  • Epigenetics
  • Hematology

Background:

  • N6-methyladenosine (m6A) is the most abundant RNA modification in eukaryotes.
  • m6A plays critical roles in normal physiological and pathological conditions, including hematopoiesis and differentiation.
  • Recent studies link m6A mRNA methylation to cell fate control in normal and malignant hematopoietic states.

Purpose of the Study:

  • To provide a comprehensive understanding of m6A's complex roles in normal hematopoietic development and malignant hematopoietic diseases.
  • To review the components, functions, and regulatory mechanisms of m6A modification regulators.
  • To explore therapeutic strategies targeting m6A for leukemia treatment.

Main Methods:

  • Systematic review of existing research on m6A regulatory factors in hematopoiesis and leukemia.
  • Overview of m6A modification regulators and their biological functions.
  • Analysis of hematopoietic stem cells and leukemia stem cells characteristics and regulatory mechanisms.

Main Results:

  • m6A modification significantly influences normal hematopoiesis and differentiation.
  • Dysregulation of m6A pathways is implicated in the development of leukemia.
  • m6A regulatory factors exhibit distinct roles in hematopoietic stem cells and leukemia stem cells.

Conclusions:

  • Targeting m6A regulators and signaling pathways presents a promising strategy for leukemia intervention.
  • m6A modification holds potential for developing more precise and effective leukemia therapies.
  • Further research into m6A mechanisms can uncover novel therapeutic targets for hematological malignancies.